- Treatment with dexrazoxane (ICRF-187) reduces Myocardial calcium overload in the experimental anthracycline-induced heart failure in rabbitsPublication without faculty affiliation
- Treatment with Dexrazoxane (ICRF-187) Reduces Myocardial Calcium Overload in the Experimental Anthracycline-Induced Heart Failure in RabbitsPublication without faculty affiliation
- Development of LC-MS/MS method for the simultaneous analysis of the cardioprotective drug dexrazoxane and its metabolite ADR-925 in isolated cardiomyocytes and cell culture medium2013 | Faculty of Pharmacy in Hradec Králové
- Catalytic Inhibitors of Topoisomerase II Differently Modulate the Toxicity of Anthracyclines in Cardiac and Cancer Cells2013 | Faculty of Pharmacy in Hradec Králové, Faculty of Medicine in Hradec Králové
- Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron2009 | Faculty of Pharmacy in Hradec Králové, Faculty of Medicine in Hradec Králové
- Anthracycline-induced cardiotoxicity: Overview of studies examining the roles of oxidative stress and free cellular iron2009 | Faculty of Medicine in Hradec Králové
- Structure-Activity Relationship Study of Dexrazoxane Analogues Reveals ICRF-193 as the Most Potent Bisdioxopiperazine against Anthracycline Toxicity to Cardiomyocytes Due to Its Strong Topoisomerase II beta Interactions2021 | Faculty of Pharmacy in Hradec Králové, Faculty of Medicine in Hradec Králové
- Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase II beta inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity2021 | Faculty of Pharmacy in Hradec Králové, Faculty of Medicine in Hradec Králové
- Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase II beta Interaction as a Prerequisite for Effective Protection against Anthracycline Cardiotoxicity2020 | Faculty of Pharmacy in Hradec Králové, Faculty of Medicine in Hradec Králové